Other substances

Indomethacin

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Small molecule	in silico	42.78		Apr/30/2020

AI-suggested references

Link	Publication date
Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors	Sep/24/2021
Widely available lysosome targeting agents should be considered as potential therapy for COVID-19	Jun/06/2020
Indomethacin-based PROTACs as pan-coronavirus antiviral agents.	Sep/04/2021
Mechanisms of Bioactivities of Fucoidan from the Brown Seaweed Fucus vesiculosus L. of the Barents Sea	Mar/09/2022
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients	Apr/10/2020
Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19	May/05/2021
Indomethacin and resveratrol as potential treatment adjuncts for SARS-CoV-2/COVID-19	Apr/18/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04344457	Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19	Recruiting	Phase 1\|Phase 2	Apr/16/2020	Sep/30/2020
Alternative id - HIZ-PRC-COVID-19 Interventions - Drug: Hydroxychloroquine\|Drug: Indomethacin\|Drug: Zithromax Oral Product Study type - Interventional Study results - No Results Available Locations - Perseverance Research Center, Scottsdale, Arizona, United States\|Covidcraz 19, Llc, New Orleans, Louisiana, United States Study designs - Allocation: N/A\|Intervention Model: Single Group Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 80 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Improvement of clinical status\|Time of clinical recovery of fever\|Time of clinical recovery of cough\|Safety as determined by changes in QTC intervals measured by ECG\|Safety as determined by presence of side effects\|Time to improvement
NCT05007522	Ketotifen and Indomethacin Combination Treatment Clinical Trial for COVID-19	Not yet recruiting	Phase 3	Dec/01/2021	Dec/01/2022
Alternative id - Pro00108924 Interventions - Drug: Ketotifen/Indomethacin\|Drug: Placebo Study type - Interventional Study results - No Results Available Locations - Dhulikhel Hospital, Kavre, Bagmati, Nepal\|Global Clinical Research Pvt. Ltd., Kathmandu, Nepal Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)\|Primary Purpose: Treatment Enrollment - 150 Age - 18 Years to 75 Years (Adult, Older Adult) Outcome measures - UCSD Shortness of Breath Questionnaire\|Development of severe disease\|Proportion and number of medically attended visits related to COVID-19\|Need for hospitalization\|Intensive care unit admission\|Supplemental oxygen\|Need for mechanical ventilation\|severe functional disability (WHO ordinal scale)\|Serum chymase concentration\|coagulation\|Patient Global Improvement Score\|Incidence of associated symptoms of COVID-19\|adverse effect profile